Home
Machine learning-based prediction of HCC among patients with CHB receiving long-term ETV/TFV therapy
Fill out patient information!
This machine learning model was trained and validated in Korean patients with CHB.
Baseline (at the start of ETV/TFV therapy)
Units
Input values
Age
Years
Sex
Female
Male
Presence of cirrhosis
No
Yes
Type of antiviral agent
Entecavir
Tenofovir
Albumin
g/dL
Bilirubin
mg/dL
Prothrombin time
INR
AST
IU/L
ALT
IU/L
Platelet counts
x1,000/mm3
HBeAg
Negative
Positive
HBV DNA
IU/mL
Ascites
None
Mild to Moderate
Severe
Encephalopathy
None
Mild to Moderate
Severe
At 5 years after the start of ETV/TFV therapy
Units
Input values
Albumin
g/dL
Bilirubin
mg/dL
Prothrombin time
INR
AST
IU/L
ALT
IU/L
Platelet counts
x1,000/mm3
HBeAg
Negative
Positive
Detection of HBV DNA
Not detected
Detected
Ascites
None
Mild to Moderate
Severe
Encephalopathy
None
Mild to Moderate
Severe